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To the Editor: In their letter entitled “Time to aban-
don the term ‘Chinese herbs nephropathy’” in the No-
vember issue of Kidney International, Dr. Chen et al
argue against continuing to use the term “Chinese herbs Bone alkaline phosphatase
nephropathy” to describe the rapidly progressive scleros-
ing interstitial nephropathy observed in women given isoforms in chronic
Chinese herbs for slimming purposes [1].
In a recent case report published in the electronic renal failure
Website edition of the November issue of American
Journal of Kidney Disease, we demonstrated that aristo- To the Editor: Congratulations to Magnusson et al
lochic acid (AA) taken in China in an herbal remedy for their article about bone-specific alkaline phosphatase
induces a typical Chinese herbs nephropathy (CHN) (bAP) and its isoforms [1]. They identified a new serum
with AA-DNA adducts and urothelial lesions [2]. Fur- bAP isoform (B1x) in ESRD patients. However, several
thermore, AA given alone to rabbits induces similar points need clarification. First, why did end-stage renal
renal and urothelial lesions [3]. The causal role of AA in disease (ESRD) patients have elevated total AP activity?
the Belgian epidemy and in at least one Chinese patient is Did any of the patients have any hepatic disorder such
thus established. We have proposed to use the term as hepatitis B or C? If not, then an increase in B2 bAP
“aristolochic acid nephropathy” in those cases in which isoform, produced by trabecular osteoblasts, will take
there is unequivocal demonstration of AA intoxication. an enormous clinical value. Second, since B2 represents
Second, in a Letter to the Editor in the same issue of more than 35% of the total bAP activity and B1 only
American Journal of Kidney Disease, Solez et al com- 4%, could the 5-fold increase of B2 solely explain the
mented on Dr. Chen’s original posting and subsequent 2.6-fold increase in total AP activity? Third, was there
discussion on the AJKD Discussion Forum and on the any difference in the absolute values of bAP [2], both
mass and activity, between healthy subjects and ESRDNEPHROL E-mail discussion group. He argued that
patients? Fourth, we and other authors have shown thatself-regulation was preferable to editorial decisions [4].
bAP positively correlate with PTH [3, 4]. How do Mag-He emphasized the difficulty to determine the content
nusson et al explain the absence of such a correlation inof herbal preparations. The term CHN had never in-
their present study?tended to denigrate the system of Chinese herbal medi-
Finally, without bone histology, the suggestion thatcine. Indeed, many useful compounds widely used in
B1x is a marker of adynamic bone is hazardous. Cer-Western medicine came from Chinese herbal medicine.
tainly, patients with positive B1x had several elements
Jean-Pierre Cosyns in favor of adynamic bone, including old age, low bAP,
Brussels, Belgium and osteocalcin. However, the same patients had para-
thyroid hormone (PTH) levels 2 to 10 times greater than
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rotic on bone mineral density?
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teopenic or osteoporotic.
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chronic renal failure (CRF) [1]. In reply to his queries
regarding questions 1 and 2, total ALP was significantly
increased; however, the majority of the patients had ac-
tivities within the reference interval for healthy adults.
We agree with the suggestion that the increase of BALP
isoform B2 in CRF patients may be clinically useful. Prediction of hypertension in
None of the patients in this study had any biochemical
or clinical evidence of hepatic disorder. To answer the hemodialysis patients
third question, we used the previously reported reference
intervals for all three BALP immunoassay kits (Alk-
To the Editor: I have read with much interest thephase-B, Tandem-R Ostase and Tandem-MP Ostase)
and refer him to Figure 2 [1]. To respond to his fourth paper by Agarwal and Lewis [1] on prediction of hyper-
tension in chronic hemodialysis patients. In the introduc-question, discordant findings between different studies
are not uncommon, which probably reflects the heteroge- tion, the authors focus on the fact that it is still uncertain
which blood pressure measurement the clinician has toneity of bone disorders in CRF patients. We did, how-
ever, find a significant correlation between the novel adopt to define hypertension in these patients. There
is no question that in the general population 24-hourBALP isoform B1x and PTH, which might contribute
to the positive correlations previously reported [2]. ambulatory monitoring is a better measure than the of-
fice measure. It is well-documented that the ambulatoryWe suggested that B1x should be further evaluated as
a marker of adynamic bone disease. This will indeed estimate is superior to the office estimate for predicting
incident cardiovascular complications, as well as left ven-require a classification of patients by bone histomorpho-
metry, which was not obtained in this study. Although trical hypertrophy (LVH) [2], which is a valid surrogate
end point. Whether or not 24-hour ambulatory monitor-adynamic bone disease is usually associated with rela-
tively low parathyroid hormone (PTH) levels, PTH may ing predicts survival and cardiovascular complications in
the dialysis population still remains to be proved. Thisfail to discriminate between adynamic and moderate
hyperparathyroid states and even high PTH levels may is important mostly because two surveys have shown
that routine pre-dialysis blood pressure and 24-hour am-occur [3]. Another important point, discussed in our pa-
per [1], is that PTH was analyzed using a commercial bulatory monitoring explain to a similar degree the vari-
ance in left ventricular mass. Both the paper by Conlonassay originally reported to detect only the intact (1-84
PTH) circulating molecule. However, it has recently et al [3] and our study based on multivariate modelling
[4] have clearly shown the strength of the associationbeen demonstrated that a fragment (most likely the 7-84
PTH) interferes with this assay [4]. Thus, the PTH values between 24-hour ambulatory monitoring and left ventri-
cal mass is not superior to that of pre-dialysis bloodreported in our study (and other studies) might well be
